Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics that, in comparison with current alternatives, show improved properties, reduced side-effects and expanded applications. The company's product development is based on its proprietary in-house nanotechnology platform, XR17.